These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 32546562

  • 1. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.
    Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Harris J, Hoi AY, Mackay F, Morand EF.
    Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32546562
    [Abstract] [Full Text] [Related]

  • 2. Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus.
    Liphaus BL, Kiss MHB, Carrasco S, Palmeira P, Goldenstein-Schainberg C, Carneiro-Sampaio M.
    Clin Rheumatol; 2017 Dec; 36(12):2847-2852. PubMed ID: 28378099
    [Abstract] [Full Text] [Related]

  • 3. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
    Tinazzi E, Puccetti A, Gerli R, Rigo A, Migliorini P, Simeoni S, Beri R, Dolcino M, Martinelli N, Corrocher R, Lunardi C.
    Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
    [Abstract] [Full Text] [Related]

  • 4. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus.
    Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF.
    Lupus; 2013 Aug; 22(9):873-84. PubMed ID: 23846230
    [Abstract] [Full Text] [Related]

  • 5. Serum sFas/sFasL ratio in systemic lupus erythematosus (SLE) is a function of age.
    Turi MC, D'Urbano M, Celletti E, Alessandri C, Valesini G, Paganelli R.
    Arch Gerontol Geriatr; 2009 Aug; 49 Suppl 1():221-6. PubMed ID: 19836636
    [Abstract] [Full Text] [Related]

  • 6. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
    Salazar-Camarena DC, Ortíz-Lazareno P, Marín-Rosales M, Cruz A, Muñoz-Valle F, Tapia-Llanos R, Orozco-Barocio G, Machado-Contreras R, Palafox-Sánchez CA.
    Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
    [Abstract] [Full Text] [Related]

  • 7. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
    Hao JH, Ye DQ, Zhang GQ, Liu HH, Dai H, Huang F, Pan FM, Su H, Dong MX, Chen H, Wang Q, Zhang XJ.
    Arch Dermatol Res; 2006 Jan; 297(7):329-32. PubMed ID: 16328345
    [Abstract] [Full Text] [Related]

  • 8. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
    Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H.
    Arthritis Rheum; 1997 Jun; 40(6):1126-9. PubMed ID: 9182923
    [Abstract] [Full Text] [Related]

  • 9. Serum levels of soluble Fas ligand in patients with silicosis.
    Tomokuni A, Otsuki T, Isozaki Y, Kita S, Ueki H, Kusaka M, Kishimoto T, Ueki A.
    Clin Exp Immunol; 1999 Dec; 118(3):441-4. PubMed ID: 10594565
    [Abstract] [Full Text] [Related]

  • 10. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
    Miret C, Font J, Molina R, Garcia-Carrasco M, Filella X, Ramos M, Cervera R, Ballesta A, Ingelmo M.
    Anticancer Res; 2001 Dec; 21(4B):3053-9. PubMed ID: 11712810
    [Abstract] [Full Text] [Related]

  • 11. Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus.
    Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Hoi AY, Harris J, Mackay F, Morand EF.
    Clin Transl Immunology; 2019 Dec; 8(4):e01047. PubMed ID: 31024730
    [Abstract] [Full Text] [Related]

  • 12. Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis.
    Musiał K, Zwolińska D.
    Apoptosis; 2011 Jul; 16(7):653-9. PubMed ID: 21516345
    [Abstract] [Full Text] [Related]

  • 13. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H, Wetterö J, Skogh T, Sjöwall C.
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [Abstract] [Full Text] [Related]

  • 14. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
    Mouawad R, Khayat D, Soubrane C.
    Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
    [Abstract] [Full Text] [Related]

  • 15. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC, Murray SL, Balakrishnan VS, Guo D, King AJ, Pereira BJ, Jaber BL.
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [Abstract] [Full Text] [Related]

  • 16. [Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].
    Jun EJ, Han JY, Sun HS.
    Korean J Hepatol; 2006 Dec; 12(4):507-14. PubMed ID: 17237628
    [Abstract] [Full Text] [Related]

  • 17. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus.
    Al-Maini MH, Mountz JD, Al-Mohri HA, El-Ageb EM, Al-Riyami BM, Svenson KL, Zhou T, Richens ER.
    Lupus; 2000 Dec; 9(2):132-9. PubMed ID: 10787011
    [Abstract] [Full Text] [Related]

  • 18. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis.
    Knipping E, Krammer PH, Onel KB, Lehman TJ, Mysler E, Elkon KB.
    Arthritis Rheum; 1995 Dec; 38(12):1735-7. PubMed ID: 8849344
    [Abstract] [Full Text] [Related]

  • 19. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.
    Yildiz R, Benekli M, Buyukberber S, Kaya AO, Ozturk B, Yaman E, Berk V, Coskun U, Yamac D, Sancak B, Uner A.
    J Cancer Res Clin Oncol; 2010 Oct; 136(10):1471-6. PubMed ID: 20155284
    [Abstract] [Full Text] [Related]

  • 20. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
    Fu Y, Xiao QM, Wang T, Chen XH, Ai YH.
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.